New source of fish fears. by unknown
Forum
case ofmonarchs, traditional wintering sites
in California and Mexico have been convert-
ed bydevelopment, deforestation, or agricul-
ture. Thus, tens ofmillions ofmonarchs are
restricted to 10 sites in Mexico (5 of them
unprotected by regulations) and only 7
remaining sites in California. The butterflies
are not yet endangered, but a major part of
theirlifecyde is injeopardy.
Outreach in elementary schools has
improved the public's appreciation ofbats.
And BCI is working with mining compa-
nies to convertabandoned mines into roosts
for hibernating bats, creating a human-ani-
mal partnership with mutual benefits. "This
is averyimportant part ofbat ecology," says
French. "We protect [both] the bats and
people with gates at the mine entrances. It
gives ahabitat for bats, and helps give mines
a more positive image."
Pollinators may also benefit from the
move toward more "natural" gardens in pri-
vate homes that demand less pesticide use,
as well as a 1994 Executive Memorandum
issued by President Clinton that recom-
mends the use of regional native plants,
which often evolved with their pollinators
in a mutually beneficial relationship, and
integrated pest management, which features
reduced use ofpesticides on federal and fed-
erally funded properties. And science is
beginning to do its part to protect pollina-
tors, as well. In a paper published in the
February 1998 issue of Conservation Biology,
Nabhan, Bitner, Inouye, and 19 othercoau-
thors propose supporting animal pollinator
services by promoting alternative pollina-
tors, encouraging crop breeders to consider
pollinator attraction in new varieties, pre-
serving pollinator stocks, and researching
ways of increasing pollination and creating
pollinator habitats inagricultural areas.
Melanoma Vaccines
Researchers are making significant progress
in developing innovative treatments for
melanoma, a form ofmalignant skin cancer
that is on the rise in the United States,
according to the American Cancer Society.
Melanoma begins in the melanocytes, the
cells that produce the skin pigment called
melanin. Researchers believe that exposure
to ultraviolet light damages the DNA in
these cells, which results in the development
ofmelanoma.
Scientists have beenworking foryears to
develop vaccines that treat melanoma by
stimulating the immune system to attack
cancer cells. The body does not ordinarily
attack melanoma cells because such cells are
roughly 99% normal, says Philip
Livingston, head of the cancer vaccinology
laboratory at Memorial Sloan-Kettering
Cancer Center in New York City.
Researchers have sought to identify the dif-
ferences that explain why some cells turn
cancerous. "We've spent many years in the
laboratory trying to define and isolate the
genetic elements and the genes that code for
what is different on a cancer cell compared
to a normal cell that the immune system
can recognize," says Steven Rosenberg, chief
ofsurgery at the National Cancer Institute
(NCI).
Livingston refers to these characteristic
elements ofcancer cells, which include pro-
teins and antigens, as "handles." Researchers
developing melanoma vaccines replicate
these handles and combine them with
immune boosters, or substances that the
immune system recognizes and attacks.
Theoretically, linking the handles with sub-
stances known to elicit an immune response
will prompt the body to seekout all handles
and therewith eliminate the cancer cells.
Although the practical application of such
vaccines is years away, scientists are making
significant advances in the area. "This is a
mammoth field," says Paul Chapman, an
associate attending physician and head of
the melanoma section at Memorial Sloan-
Kettering Cancer Center. "There are many
vaccines that are being tested, and all are
equallypromising."
Researchers at Memorial Sloan-
Kettering are working on melanoma vac-
cines that contain one of three replicated
chemicals-GM2, GD2, or GD3-that are
located on melanoma cells and that have
been found to be recognized by the
immune system. The vaccines combine the
chemicals with QS21, an immune booster
from the South American soapbark tree,
and KLH, an antigen produced by the mol-
lusk Megathura crenulata. Early results show
an improvement in survival rates in some
patients.
Rosenberg and colleagues at the NCI
have chosen to work with cancer cell pep-
tides that the immune system can recognize.
They have modified the peptides so they
can better bind to the immune cells-cyto-
toxic T lymphocytes-that attack
melanoma cells. The modified peptides are
then injected into the body. In a recent
study published in the March 1998 issue of
Nature Medicine, Rosenberg and colleagues
reported that, when administered with
interleukin-2, a medication that boosts the
immune system to help slow the growth of
cancer, the vaccine caused an immune sys-
tem response. They also found that 13 of31
patients showed at least partial tumor
shrinkage in the lung or skin, among other
sites.
Another promising vaccine has been
developed by Donald Morton and col-
leagues at the John Wayne Cancer Institute
in Santa Monica, California. Morton col-
lected blood, tissue, and serum samples
from melanoma patients for many years.
Study ofthese samples enabled him to iden-
tify three cancer cell lines that provoke
strong immune system responses. Morton is
working on a vaccine that uses radiated
melanoma cells containing many different
handles combined with bacillus Calmette-
Guerin, a known immune booster. Morton
is currently conducting worldwide clinical
trials on thevaccine.
New Source of Fish Fears
In the Snook Nook bait shop in Jensen
Beach, Florida, snapshots ofanglers holding
up their prize catches attest to the rich
bounty for which the adjacent Indian River
is famous. A few yards from the shop, in a
cramped trailer owned by the Florida
Department of Environmental Protection
(DEP), is another photographic testament
to the Indian River's fish. These close-up
shots show fish with bloody, open sores
reminiscent of those associated with the
toxic dinoflagellate Pfiesteriapiscicida.
The sickened fish in the photos began
appearing early this spring on the hooks of
anglers fishing around the juncture of
Florida's Indian and St. Lucie rivers, a
brackish region known as the St. Lucie
Estuary. At least 33 species of fish were
affected. Although the lesions mimic those
associated with the Pfiesteria outbreaks that
have killed millions offish in Maryland and
North Carolina, the estuary apparently har-
bors a different culprit; nearly all the sick-
ened fish in the estuarywere found alive.
Water samples revealed the presence of
Cryptoperidiniopsis ("crypto"), one of10 rec-
ognized Pfiesteria-like species ofmicroalgae.
Karen Steidinger, a senior research scientist,
andJan Landsberg, aresearch scientist, both
of the DEP's Florida Marine Research
Institute in St. Petersburg, first identified
crypto in 1997 in water samples taken from
St. John's River near Jacksonville. Like
Pfiesteria, crypto is a heterotrophic dinofla-
gellate that feeds on microalgal prey. Crypto
coexists with Pfiesteria in Maryland and
North Carolina, but appears to live apart
from anyrelated species in Florida.
Whether it's causing the ulcers in the St.
Lucie fish, though, is not clear. Of the
2,000 known species of dinoflagellates,
about 65 have been shown to produce tox-
ins. "There's no evidence [crypto] is toxic,"
says JoAnn Burkholder, an associate profes-
sor ofbotany and aquatic ecology at North
Carolina State University in Raleigh, who
in 1991 helped identify Pfiesteria. "We
don't understand much about toxin pro-
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duction in dinoflagellates." Whatever is
plaguing the St. Lucie fish appears to act by
destroying the protective mucous coat of
the fish, inviting opportunistic bacterial and
fungal infections.
Burkholder, Steidinger, and other
researchers are scrambling to determine
whether crypto is indeed toxic, and to solve
the mystery of the sickened fish. "It's
extremely important from a public health
perspective to know what's out there, what
are its toxins and their effects," Steidinger
says. Sometime this summer, researcher
Peter Moeller, project leader for the marine
biotoxins program at the National Ocean
Service in Charleston, South Carolina,
expects to have preliminary results ofbioas-
says he's conducting to determine crypto's
toxins. His findings should aid in under-
standing both crypto and its cousins.
According to Daniel Baden, director of
the NIEHS Marine and Freshwater
Biomedical Sciences Center at the
University of Miami in Florida, three tox-
ins have been associated with Pfiesteria-like
dinoflagellates-a lipid-soluble lethal
toxin, a water-soluble suspected neurotox-
in, and a dermonecrotic toxin. Baden spec-
ulates that lesions found on fish killed by
Pfiesteria may actually be caused by crypto.
"People have been working with mixed
cultures," he says, "but because the organ-
isms were differentiated only recently, we
haven't had time to ascribe specific toxins
to specific organisms."
Some researchers hope to ward off
future outbreaks by determining what
caused an ancient species of microalgae to
strike here and now. "We believe crypto has
been here hundreds, maybe thousands of
years," says DEP marine biologist Ann
Forstchen. Four times over the last 20 years,
the St. Lucie Estuary has suffered outbreaks
of fish disease. Each followed unusually
high discharges from the St. Lucie Canal
into the St. Lucie River, in which the South
Florida Water Management District flushed
fresh water from Lake Okeechobee through
the canal to prevent flooding. "There's an
apparent causal relationship between mas-
sive discharges and the outbreak of ulcers,"
says Dan Haunert, a lead scientist with the
South Florida Water Management District.
Nutrient runoffinto the canal is believed to
promote microalgal growth while the force
of the discharges is thought to push the
growth up from the bottom sediment.
Although studies are incomplete, crypto
appears to have little, if any, effect on
humans. Two months into the St. Lucie
outbreak, the Florida Department ofHealth
had received fewer than tWO dozen com-
plaints from people who suspected they had
been harmed by contact with the river
water. "We haven't seen a
clear association between
exposure and illness," says
epidemiologist Alan
Rowan. "[People are]
reporting various symp-
toms and they've had a
wide range of exposures,
from one day to five years.
There may be alternative
explanations."
New water worries. Cryptoperidiniopsis, a species of microalgae, may
be causing sick fish-and concerns for human health.
As freshwater discharges dropped off in
April, so did the number of diseased fish
brought to the DEP's trailer outside the
Snook Nook. Scientists believe the fish dis-
ease event may have run its course. But
Forstchen expects it to return, just as she
expects the periodic return of unseasonably
heavy rains. "I don't thinkwe'll be in a posi-
tion to stop [outbreaks]," she says, "but we
maybeable to predictwhen they'll happen."
Lasers for Lungs
Lung cancer is one of the deadliest cancers
in the United States, striking an estimated
190,000 people and killing 160,000 annu-
ally. Smoking is the major cause of lung
cancer worldwide,but asbestos, air pollu-
tion, and radon appear to contribute to this
disease. By the time cancers of the lung
become visible through conventional diag-
nostics, they frequently are too far advanced
to treat successfully. Now, Xillix
Technologies Corporation of Richmond,
British Columbia, has developed a technol-
ogy that allows much earlier diagnosis of
these dangerous cancers, possibly helping to
save lives. The device was approved by the
U.S. Food and DrugAdministration (FDA)
for use on lung cancers on 20 September
1996.
The lethal nature ofnon-small cell lung
cancer (NSCLC) lies largely in the fact that,
by the time the tumor becomes visible to
the oncologist, it has spread too widely to
be successfully surgically removed or irradi-
ated. Chemotherapy also has had very limit-
ed success against lung cancer. Sixty-five
percent ofstage I cancers, 50-55% ofstage
II cancers, and 30% ofstage III cancers are
cured. But most lung cancers are not caught
until stage 3 or 4, says Tracy Lee Weigel, an
assistant professor ofsurgery and director of
the LIFE-Lung Bronchoscopy Program at
the University of Pittsburg School of
Medicine in Pennsylvania. For all those
diagnosed with NSCLC, she says, the five-
year survival rate is about 13-14%.
The new technology, which Xillix calls
the Lung Imaging Fluorescence Endoscopy
bronchoscopic system, or LIFE-Lung, helps
doctors detect lung cancers 1-2 years earlier
than standard bronchoscopy, says Weigel.
This can make all the difference in catching
the disease in time. "We can [detect lung
cancers] before they've broken through the
basement membrane [of the lung], before
they've gained access to the lymphatics and
the bloodstream and develop the potential
to metastasize," she says.
The LIFE-Lung works according to sim-
ple principals. Tissue fluoresces when illu-
minatedwith laser light, but the autofluores-
cent properties ofnormal and malignant tis-
sues differ. A physician uses the LIFE-Lung
bronchoscope-a laser hooked to a flexible
fiberoptic endoscope-to shine light onto
the lungs through the fiberoptic imaging
bundle ofthe scope. The fluorescence given
offby the illuminated tissue is relayed back
through a second imaging bundle and
observed directly by the physician. With the
LIFE-Lung, healthy lung tissue appears
green and abnormal tissue appears red. In
clinical trials, the LIFE-Lung was "171%
more sensitive in picking up abnormalities
than white light," says Harvey Pass, aprofes-
sor ofsurgery and oncology at Wayne State
University in Detroit, Michigan, and pro-
gram director for the Barbara Ann
Karmanos Cancer Institute in Detroit. A
similar device, which uses a computer algo-
rithm to distinguish between the subtle dif-
ferences in the wavelengths of fluorescent
light given offby normal and malignant tis-
sues, is in development at Oak Ridge
National Laboratory in Tennessee.
Differential fluorescence does not
replace biopsy, says Bergein F. Overholt,
president of Gastrointestinal Associates in
Knoxville, Tennessee, a company involved
in the development of the Oak Ridge
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